Alterity Therapeutics - ATHE Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $2.50
  • Forecasted Upside: 587.00 %
  • Number of Analysts: 2
  • Breakdown:
  • 0 Sell Ratings
  • 1 Hold Ratings
  • 1 Buy Ratings
  • 0 Strong Buy Ratings
$0.36
▼ -0.01 (-2.67%)

This chart shows the closing price for ATHE by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Alterity Therapeutics Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for ATHE and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for ATHE

Analyst Price Target is $2.50
▲ +587.00% Upside Potential
This price target is based on 2 analysts offering 12 month price targets for Alterity Therapeutics in the last 3 months. The average price target is $2.50, with a high forecast of $3.00 and a low forecast of $2.00. The average price target represents a 587.00% upside from the last price of $0.36.

This chart shows the closing price for ATHE for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Buy

The current consensus among 2 polled investment analysts is to buy stock in Alterity Therapeutics.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
6/12/2021
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
9/10/2021
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
12/9/2021
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
3/9/2022
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
6/7/2022
  • 0 strong buy ratings
  • 1 buy ratings
  • 1 hold ratings
  • 0 sell ratings
9/5/2022
  • 0 strong buy ratings
  • 1 buy ratings
  • 1 hold ratings
  • 0 sell ratings
11/4/2022
  • 0 strong buy ratings
  • 1 buy ratings
  • 1 hold ratings
  • 0 sell ratings
12/4/2022

Latest Recommendations

  • 0 strong buy ratings
  • 1 buy ratings
  • 1 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
8/3/2022LADENBURG THALM/SH SHInitiated CoverageBuy$2.00Low
6/23/2022The Goldman Sachs GroupLower TargetNeutral$11.00 ➝ $3.00Low
8/20/2021BenchmarkInitiated CoverageSpeculative Buy$4.00Medium
(Data available from 12/4/2017 forward)

News Sentiment Rating

1.11 (Buy)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 1 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
5/8/2022
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
6/7/2022
  • 2 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
7/7/2022
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
8/6/2022
  • 1 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
9/5/2022
  • 2 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
10/5/2022
  • 1 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
11/4/2022
  • 1 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
12/4/2022

Current Sentiment

  • 1 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.

Positive

Alterity Therapeutics logo
Alterity Therapeutics Limited engages in the research and development of therapeutic drugs to treat Alzheimer's disease, Huntington disease, Parkinson's disease, and other neurological disorders in Australia. The company's lead drug candidate is ATH434 that has completed Phase I clinical trial for the treatment of Parkinson's disease. It is also developing PBT2 that has completed Phase 2a clinical trial to treat Alzheimer's disease. The company was formerly known as Prana Biotechnology Limited and changed its name to Alterity Therapeutics Limited in April 2019. Alterity Therapeutics Limited was incorporated in 1997 and is headquartered in Melbourne, Australia.
Read More

Today's Range

Now: $0.36
Low: $0.36
High: $0.38

50 Day Range

MA: $0.41
Low: $0.35
High: $0.49

52 Week Range

Now: $0.36
Low: $0.35
High: $1.23

Volume

28,537 shs

Average Volume

49,964 shs

Market Capitalization

$14.60 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.15

Frequently Asked Questions

What sell-side analysts currently cover shares of Alterity Therapeutics?

The following Wall Street research analysts have issued stock ratings on Alterity Therapeutics in the last twelve months: LADENBURG THALM/SH SH, and The Goldman Sachs Group, Inc..
View the latest analyst ratings for ATHE.

What is the current price target for Alterity Therapeutics?

2 Wall Street analysts have set twelve-month price targets for Alterity Therapeutics in the last year. Their average twelve-month price target is $2.50, suggesting a possible upside of 587.0%. The Goldman Sachs Group, Inc. has the highest price target set, predicting ATHE will reach $3.00 in the next twelve months. LADENBURG THALM/SH SH has the lowest price target set, forecasting a price of $2.00 for Alterity Therapeutics in the next year.
View the latest price targets for ATHE.

What is the current consensus analyst rating for Alterity Therapeutics?

Alterity Therapeutics currently has 1 hold rating and 1 buy rating from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe ATHE will outperform the market and that investors should add to their positions of Alterity Therapeutics.
View the latest ratings for ATHE.

What other companies compete with Alterity Therapeutics?

How do I contact Alterity Therapeutics' investor relations team?

Alterity Therapeutics' physical mailing address is LEVEL 3 460 BOURKE STREET, MELBOURNE C3, VIC 3000. The company's listed phone number is (139) 349-4906 and its investor relations email address is [email protected] The official website for Alterity Therapeutics is www.alteritytherapeutics.com. Learn More about contacing Alterity Therapeutics investor relations.